Zantac Information

Sanofi is excited to introduce ZANTAC 360°® with famotidine, an all-in-one heartburn medicine that gives consumers the flexibility to prevent and relieve heartburn fast.

Building on the Zantac brand’s established history and legacy of offering heartburn relief solutions, Zantac 360° with famotidine offers consumers a heartburn option that can help prevent and relieve heartburn fast.

Zantac 360° contains the active ingredient famotidine, a clinically proven, safe, and effective medicine that is doctor recommended and FDA approved. Famotidine is an H2 blocker that works to relieve heartburn symptoms by reducing stomach acid and starts working to prevent heartburn when taken as little as 15 minutes before eating or drinking.

The voluntary recall of Zantac® OTC products containing ranitidine left heartburn sufferers with a void. Zantac 360° with famotidine provides an all-in-one solution that prevents and relieves heartburn.

Frequently Asked Questions

  • Zantac 360° contains famotidine, a doctor recommended and FDA approved medicine to relieve and prevent heartburn symptoms.

  • Yes. Zantac 360° contains the active ingredient famotidine, a clinically proven, safe, and effective medicine that is doctor recommended and FDA approved. Famotidine is an H2 blocker that works to relieve heartburn symptoms fast by reducing the production of stomach acid and prevents heartburn when taken as little as 15 minutes before eating or drinking.

  • No. Sanofi voluntarily recalled all Zantac ranitidine products in the U.S. and Canada in October 2019 and does not plan to relaunch Zantac products with ranitidine at this time.

    Below is a timeline of events.

    September 2019

    The U.S. Food and Drug Administration (FDA) announces some ranitidine medicines contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels and Sanofi begins to evaluate NDMA levels in Zantac®.

    October 2019

    As a precautionary measure, Sanofi issues a voluntary recall of all Zantac products which contained ranitidine in the U.S. and Canada while evaluations of ranitidine are ongoing.

    April 1, 2020

    FDA announces findings that NDMA levels in some ranitidine products increase with time and when stored at higher than room temperatures and requests the withdrawal of all prescription and over-the-counter ranitidine products from the market.

    April 2021

    Sanofi releases Zantac 360° formulated with famotidine, a clinically proven, safe, and effective medicine that is doctor recommended and FDA approved.

  • The active ingredient in Zantac 360°, famotidine, has been evaluated and tested and there is no risk of NDMA above FDA-established acceptable limits.